SCHEMBL22747375

SCHEMBL22747375

CNS(=O)(=O)c1cc(C)c(Nc2cccc(C(F)(F)F)c2)c(Br)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.56
▸ RAPGEF4 Q8WZA2 1/20 0.55
▸ FFAR1 O14842 1/20 0.48
▸ CDK1 P06493 1/20 0.48
▸ CCNB1 P14635 1/20 0.48
▸ CCNA2 P20248 1/20 0.48
▸ CDK2 P24941 1/20 0.48
▸ CDK7 P50613 1/20 0.48
▸ CCNH P51946 1/20 0.48
▸ CCNA1 P78396 1/20 0.48
▸ FFAR4 Q5NUL3 1/20 0.48
▸ CYP1A2 P05177 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ TNNI3K Q59H18 4/20 0.46
▸ BRAF P15056 1/20 0.45
▸ KDM4E B2RXH2 2/20 0.44
▸ GAA P10253 1/20 0.44
▸ IDH2 P48735 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22747536 0.83 MAPT (0.53) MAPTRAPGEF4FFAR1CDK1CCNB1
SCHEMBL22747359 0.83 MAPT (0.53) MAPTRAPGEF4FFAR1CDK1CCNB1
SCHEMBL22747538 0.82 MAPT (0.52) MAPTRAPGEF4FFAR1CDK1CCNB1
SCHEMBL20779650 0.82 MAPT (0.62) MAPTFFAR1CDK1CCNB1CCNA2
SCHEMBL22747365 0.80 MAPT (0.49) MAPTRAPGEF4FFAR1CDK1CCNB1
SCHEMBL22747253 0.79 MAPT (0.48) MAPTRAPGEF4FFAR1CDK1CCNB1
SCHEMBL22829737 0.73 RAPGEF4 (0.53) RAPGEF4FFAR1CDK1CCNB1CCNA2
SCHEMBL5184452 0.72 CA1 (0.70) MAPTFFAR1CDK1CCNB1CCNA2
SCHEMBL29602601 0.71 MAPT (1.00) MAPTFFAR1CDK1CCNB1CCNA2
SCHEMBL31331710 0.71 MAPT (0.49) MAPTCYP1A2CYP3A4CYP2C19LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11760728-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2023-09-19 — — US disclosed
US-11760728-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2023-09-19 — — US disclosed
WO-2020243415-A2 TEAD INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2020-12-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11760728-B2 Tead inhibitors and uses thereof TEAD2, TEAD3, TEAD4 MAPT 507/4885RAPGEF4 687/4885FFAR1 4644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback